Deutsche Bank AG Sells 30,534 Shares of Guardant Health, Inc. (NASDAQ:GH)

Deutsche Bank AG lessened its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 3.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 746,636 shares of the company's stock after selling 30,534 shares during the quarter. Deutsche Bank AG owned approximately 0.60% of Guardant Health worth $31,807,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GH. NewEdge Advisors LLC raised its holdings in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after acquiring an additional 230 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Guardant Health in the 4th quarter worth $61,000. GF Fund Management CO. LTD. bought a new position in Guardant Health in the 4th quarter worth $79,000. TD Waterhouse Canada Inc. raised its holdings in Guardant Health by 126.2% in the 4th quarter. TD Waterhouse Canada Inc. now owns 2,929 shares of the company's stock worth $89,000 after acquiring an additional 1,634 shares during the period. Finally, CWM LLC raised its holdings in Guardant Health by 180.3% in the 1st quarter. CWM LLC now owns 2,296 shares of the company's stock worth $98,000 after acquiring an additional 1,477 shares during the period. Institutional investors own 92.60% of the company's stock.

Guardant Health Stock Performance

NASDAQ GH traded down $1.48 during trading on Friday, hitting $58.88. The stock had a trading volume of 3,196,497 shares, compared to its average volume of 2,398,808. The company has a market capitalization of $7.34 billion, a PE ratio of -17.58 and a beta of 1.43. The company's 50-day moving average price is $49.00 and its two-hundred day moving average price is $45.48. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $60.68.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. During the same period in the prior year, the company earned ($0.84) earnings per share. The business's quarterly revenue was up 31.0% compared to the same quarter last year. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on GH shares. UBS Group raised their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Raymond James Financial raised their price objective on shares of Guardant Health from $59.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, July 31st. Mizuho lifted their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Friday, June 13th. Evercore ISI upgraded shares of Guardant Health to a "strong-buy" rating in a research note on Monday, July 14th. Finally, Stifel Nicolaus lifted their price target on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Sixteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $57.50.

Insiders Place Their Bets

In related news, Director Ian T. Clark sold 6,672 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total value of $322,791.36. Following the sale, the director directly owned 9,851 shares of the company's stock, valued at $476,591.38. This trade represents a 40.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Meghan V. Joyce sold 3,337 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $47.22, for a total value of $157,573.14. Following the completion of the sale, the director directly owned 11,150 shares in the company, valued at $526,503. This trade represents a 23.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 235,516 shares of company stock valued at $11,848,754 over the last ninety days. 6.10% of the stock is owned by insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.